EE200300156A - Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine - Google Patents

Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine

Info

Publication number
EE200300156A
EE200300156A EEP200300156A EEP200300156A EE200300156A EE 200300156 A EE200300156 A EE 200300156A EE P200300156 A EEP200300156 A EE P200300156A EE P200300156 A EEP200300156 A EE P200300156A EE 200300156 A EE200300156 A EE 200300156A
Authority
EE
Estonia
Prior art keywords
inhibition
growth factor
cell growth
tumor cell
factor dependence
Prior art date
Application number
EEP200300156A
Other languages
English (en)
Inventor
Lichtner Rosemarie
Fuhrmann Ulrike
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051609A external-priority patent/DE10051609A1/de
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200300156A publication Critical patent/EE200300156A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300156A 2000-10-18 2001-10-17 Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine EE200300156A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en) 2000-10-18 2001-10-17 Use of inhibitors of progesterone receptor for treating cancer

Publications (1)

Publication Number Publication Date
EE200300156A true EE200300156A (et) 2003-08-15

Family

ID=26007397

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300156A EE200300156A (et) 2000-10-18 2001-10-17 Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine

Country Status (26)

Country Link
EP (1) EP1414465B1 (et)
JP (1) JP4335525B2 (et)
KR (1) KR20030044006A (et)
CN (1) CN1311833C (et)
AT (1) ATE339208T1 (et)
AU (2) AU2002215958B2 (et)
BG (1) BG107745A (et)
BR (1) BR0114677A (et)
CA (1) CA2423013A1 (et)
CY (1) CY1106289T1 (et)
CZ (1) CZ299945B6 (et)
DE (1) DE60123138T2 (et)
DK (1) DK1414465T3 (et)
EA (1) EA005945B1 (et)
EE (1) EE200300156A (et)
ES (1) ES2272561T3 (et)
HK (1) HK1071697A1 (et)
HR (1) HRP20030386A2 (et)
HU (1) HUP0301461A3 (et)
IL (2) IL154974A0 (et)
MX (1) MXPA03002953A (et)
NO (1) NO20031745D0 (et)
NZ (1) NZ545965A (et)
PL (1) PL366415A1 (et)
SK (1) SK4752003A3 (et)
WO (1) WO2002032429A2 (et)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) * 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
FR2789393B1 (fr) * 1999-02-05 2001-10-12 Centre Nat Rech Scient Lactol steroidique

Also Published As

Publication number Publication date
IL154974A0 (en) 2003-10-31
BR0114677A (pt) 2003-10-07
JP2004513094A (ja) 2004-04-30
ES2272561T3 (es) 2007-05-01
NO20031745L (no) 2003-04-15
CY1106289T1 (el) 2011-10-12
HUP0301461A3 (en) 2010-01-28
HRP20030386A2 (en) 2005-04-30
CN1311833C (zh) 2007-04-25
PL366415A1 (en) 2005-01-24
MXPA03002953A (es) 2003-08-07
CZ299945B6 (cs) 2008-12-29
NO20031745D0 (no) 2003-04-15
CN1551772A (zh) 2004-12-01
HK1071697A1 (en) 2005-07-29
EP1414465A2 (en) 2004-05-06
KR20030044006A (ko) 2003-06-02
AU1595802A (en) 2002-04-29
JP4335525B2 (ja) 2009-09-30
WO2002032429A2 (en) 2002-04-25
EA005945B1 (ru) 2005-08-25
BG107745A (bg) 2004-01-30
NZ545965A (en) 2007-09-28
EA200300468A1 (ru) 2003-10-30
CA2423013A1 (en) 2002-04-25
DE60123138T2 (de) 2007-09-13
AU2002215958B2 (en) 2006-08-17
DE60123138D1 (de) 2006-10-26
DK1414465T3 (da) 2007-01-29
WO2002032429A3 (en) 2004-02-19
SK4752003A3 (en) 2003-10-07
ATE339208T1 (de) 2006-10-15
IL154974A (en) 2007-05-15
AU2002215958C1 (en) 2002-04-29
HUP0301461A2 (hu) 2003-10-28
EP1414465B1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
EE05430B1 (et) Imidasolo-5-l-2-anilino-primidiinid raku proliferatsiooni inhibitsiooni agensitena
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
NO20003600L (no) Kalium kanal inhibitorer
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
DK1150714T3 (da) Fremgangsmåder til inhibering af hjernetumorvækst
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
DK1242060T3 (da) Behandling af metastatisk sygdom
WO2006044869A8 (en) Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
DE60011755D1 (de) Calciumkanalblocker als antikrebsmittel
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
BR0317708A (pt) Composto, composição farmacêutica, e, uso de um composto
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
ATE420661T1 (de) Zellproliferation-inhibitoren
NO20034245D0 (no) Aromataseinhibering for å öke kunstig befruktning
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
ECSP003651A (es) Nuevos compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento